Utilizing Real-World Data and Algorithmic Analyses to Assess Post-Market Clinical Outcomes in Patients Switching Amongst Therapeutically Equivalent Complex Generic Drug Products and Reference Listed Drugs (U01) Clinical Trial Not Allowed
Department of Health and Human Services, Food and Drug Administration
Forecast: posting date not announced yet
Forecast details
- Status
- Forecast: posting date not announced yet
- Estimated post date
- Not stated
- Estimated application due date
- Not stated
- Estimated award date
- Not stated
- Estimated project start
- Not stated
- Fiscal year
- 2024
- Forecast posted
- Nov 24, 2023
- Funding opportunity number
- FOR-FD-24-003
- Grants.gov ID
- 351125
- Funding instrument
- Cooperative Agreement
- Category of funding
- Agriculture, Consumer Protection, Food and Nutrition
- Opportunity category
- Discretionary
- Award ceiling
- $300,000 (estimate)
- Award floor
- $300,000 (estimate)
- Total program funding
- Not stated
- Expected awards
- 1
- Cost sharing required
- No
- Assistance Listing (ALN/CFDA)
- 93.103 — Food and Drug Administration Research
Who can apply
Businesses are among the eligible applicants listed on Grants.gov.
- Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education
- Special district governments
- Native American tribal organizations (other than Federally recognized tribal governments)
- Public housing authorities/Indian housing authorities
- Small businesses
- Unrestricted (i.e., open to any type of entity above), subject to any clarification in text field entitled "Additional Information on Eligibility"
- City or township governments
- Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education
- County governments
- Independent school districts
- Public and State controlled institutions of higher education
- Native American tribal governments (Federally recognized)
- Private institutions of higher education
- For profit organizations other than small businesses
- State governments
Additional information on eligibility
Applicant organizations may submit more than one application, provided that each application is scientifically distinct. The FDA will not accept duplicate or highly overlapping applications under review at the same time per 2.3.7.4 Submission of Resubmission Application. This means that the NIH or FDA will not accept:•A new (A0) application that is submitted before issuance of the summary statement from the review of an overlapping new (A0) or resubmission (A1) application.•A resubmission (A1) application that is submitted before issuance of the summary statement from the review of the previous new (A0) application.•An application that has substantial overlap with another application pending appeal of initial peer review (see 2.3.9.4 Similar, Essentially Identical, or Identical Applications).
This product uses the Grants.gov API but is not endorsed or certified by the U.S. Department of Health and Human Services.
Description
Announcement and documents
No attachments listed in the Grants.gov data. Check the official listing for documents.
Grantor contact
The agency contact for this forecast is listed on the official Grants.gov forecast. We don't copy personal contact details from forecasts.
Grants: Grants.gov (federal grant opportunities) · last updated Nov 20, 2026, 4:20 PM ET.
This product uses the Grants.gov API but is not endorsed or certified by the U.S. Department of Health and Human Services.
Always confirm details, amendments and deadlines on the official listing. Government Bid Finder is an independent service and is not affiliated with or endorsed by the U.S. government.